79 related articles for article (PubMed ID: 32551999)
1. TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Morabito F; Gentile M; Monti P; Recchia AG; Menichini P; Skafi M; Atrash M; De Luca G; Bossio S; Al-Janazreh H; Galimberti S; Salah Z; Morabito L; Mujahed A; Hindiyeh M; Dono M; Fais F; Cutrona G; Neri A; Tripepi G; Fronza G; Ferrarini M
Expert Opin Investig Drugs; 2020 Aug; 29(8):869-880. PubMed ID: 32551999
[TBL] [Abstract][Full Text] [Related]
2. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract][Full Text] [Related]
3. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract][Full Text] [Related]
4. Exploring the future of research in the Tp53 field.
Levine AJ
Cell Death Differ; 2022 May; 29(5):893-894. PubMed ID: 35383291
[No Abstract] [Full Text] [Related]
5. Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Monti P; Lionetti M; De Luca G; Menichini P; Recchia AG; Matis S; Colombo M; Fabris S; Speciale A; Barbieri M; Gentile M; Zupo S; Dono M; Ibatici A; Neri A; Ferrarini M; Fais F; Fronza G; Cutrona G; Morabito F
Sci Rep; 2020 Oct; 10(1):18427. PubMed ID: 33116240
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of
Monti P; Menichini P; Speciale A; Cutrona G; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Front Oncol; 2020; 10():593383. PubMed ID: 33194757
[TBL] [Abstract][Full Text] [Related]
7. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Gentile M; Martino EA; Visentin A; Coscia M; Reda G; Sportoletti P; Mauro FR; Laurenti L; Varettoni M; Murru R; Chiarenza A; Vigna E; Mendicino F; Lucia E; Bossio S; Recchia AG; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vitale C; Tripepi G; D'Arrigo G; Angeletti I; Bomben R; Neri A; Cutrona G; Fronza G; Di Raimondo F; Gaidano G; Cuneo A; Foà R; Ferrarini M; Trentin L; Gattei V; Morabito F
Blood Cancer J; 2020 Sep; 10(9):92. PubMed ID: 32938904
[No Abstract] [Full Text] [Related]
8. Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.
Levin MD; Kater AP; Mattsson M; Kersting S; Ranti J; Thi Tuyet Tran H; Nasserinejad K; Niemann CU
BMJ Open; 2020 Oct; 10(10):e039168. PubMed ID: 33060089
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for Chronic Lymphocytic Leukemia with
Ahn IE; Tian X; Wiestner A
N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
[No Abstract] [Full Text] [Related]
11. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Morabito F; Tripepi G; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Al-Janazreh H; Vigna E; Martino EA; Mendicino F; Cassin R; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Monti P; Menichini P; Cutrona G; Jaksic O; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Eur J Haematol; 2021 Apr; 106(4):493-499. PubMed ID: 33378569
[TBL] [Abstract][Full Text] [Related]
12. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Bossio S; Varettoni M; Murru R; Chiarenza A; Visentin A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Recchia AG; Rossi FM; Zucchetto A; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; D'Arrigo G; Galimberti S; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Neri A; Fronza G; Cutrona G; Jaksic O; Olivieri J; Rossi D; Di Raimondo F; Cuneo A; Gaidano G; Polliack A; Trentin L; Foà R; Ferrarini M; Gattei V; Gentile M
Am J Hematol; 2021 Aug; 96(8):E306-E310. PubMed ID: 33989438
[No Abstract] [Full Text] [Related]
13. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eichhorst B; Robak T; Montserrat E; Ghia P; Niemann CU; Kater AP; Gregor M; Cymbalista F; Buske C; Hillmen P; Hallek M; Mey U;
Ann Oncol; 2021 Jan; 32(1):23-33. PubMed ID: 33091559
[No Abstract] [Full Text] [Related]
14. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
15. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Malcikova J; Pavlova S; Kunt Vonkova B; Radova L; Plevova K; Kotaskova J; Pal K; Dvorackova B; Zenatova M; Hynst J; Ondrouskova E; Panovska A; Brychtova Y; Zavacka K; Tichy B; Tom N; Mayer J; Doubek M; Pospisilova S
Blood; 2021 Dec; 138(25):2670-2685. PubMed ID: 33945616
[TBL] [Abstract][Full Text] [Related]
16. From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.
González-Gascón-Y-Marín I; Muñoz-Novas C; Rodríguez-Vicente AE; Quijada-Álamo M; Hernández-Sánchez M; Pérez-Carretero C; Ramos-Ascanio V; Hernández-Rivas JÁ
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917885
[TBL] [Abstract][Full Text] [Related]
17. Revisiting Richter transformation in the era of novel CLL agents.
Petrackova A; Turcsanyi P; Papajik T; Kriegova E
Blood Rev; 2021 Sep; 49():100824. PubMed ID: 33775465
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.
Kikushige Y
J Clin Exp Hematop; 2020 Dec; 60(4):146-158. PubMed ID: 33148933
[TBL] [Abstract][Full Text] [Related]
19. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations.
Jondreville L; Krzisch D; Chapiro E; Nguyen-Khac F
Am J Hematol; 2020 Nov; 95(11):1361-1367. PubMed ID: 32777106
[TBL] [Abstract][Full Text] [Related]
20. Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis.
Molica S; Giannarelli D
Leukemia; 2021 Feb; 35(2):615-618. PubMed ID: 32565543
[No Abstract] [Full Text] [Related]
[Next] [New Search]
